According to JPM, AI is not killing jobs (the skeptic adds on "yet, anyways"). So it's not one of the factors contributing to the brutal biopharma job market
1
1
199
Built a free biologics COGS estimator covering mAbs, recombinant proteins, ADCs, and C>, with GMP/Tox/RG options.
For founders, investors, and BD folks who need a defensible cost figure for pitching/evaluating.
Feedback welcome; still iterating!
biologics.tools
Loved this interview with @JMaraganore moderated by Bill Chin this evening
1
104
I very much enjoyed speaking with students in the Biotech Enterprise course @Northeastern this past Friday. I shared my experience & learnings on fundraising for biotech startups with some very curious and smart students!
1
218
Back to venture: Seed & Series A continue to have tough competition for dollars versus Series B opportunities, and have more tranching structures. All suggests more caution from VCs. .../4
1
99
with the biggest gains for preclinical and phase 1 stage assets, while upfronts for phase 2 assets are declining. Suggests more competition for attractive assets, even if a bit earlier in dev. .../3
1
9



















